Category:

Mike Glaicar, Business Development: Pharmacy Times...(PTNN) This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.

Two sides of one coin will keep diabetes drug sales growing--big time--through 2025. The disease is growing fast around the world, and treatment arbiters advise a more aggressive approach to blood-sugar control...Combine those two drivers, and diabetes will account for almost $60 billion in 2025 sales across 9 major global markets, GlobalData analysts say in a recent report...But this rising tide of sales won’t lift all treatments equally...Best positioned for growth? GLP-1 drugs, they say, which are poised to grow by 12.4% annually through the next decade...Right now, only a small number of patients are actually hitting blood glucose targets of 7% to 7.5% A1C levels...Doctors are pushing harder to hit those goals, so the number of people needing a second or third add-on drug will mushroom over the next 10 years. "[W]e’ll treat these people fairly aggressively" to get to those A1C levels..."[W]e are not going to tolerate people after 8.5% and 9% like we used to."...despite public health campaigns and awareness campaigns, people will "continue to overeat and under-exercise and they are going to see their weight continue to go up, and therefore their need for more medications will go up with it,"...

Frustrated by the rising cost of prescription drugs, California health advocates hope sunlight and a dose of shame will discourage drugmakers from raising their prices too quickly or introducing new medications at prices that break the bank...They're promoting legislation that would require drugmakers to provide advance notice before making big price increases. Pharmaceutical companies have come out in force against the measure, warning it would lead to dangerous drug shortages...California's SB1010 would require pharmaceutical companies to provide advance notice to drug purchasers before increasing the price of a drug by 10 percent or $10,000 a year. For generics, the threshold is $100 a month or 25 percent. Insurance companies would be required to report data on drug prices to state regulators, including the portion of premiums attributable to pharmaceuticals...Proponents hope the advance notice will give governments, insurers and pharmacy benefit managers a chance to negotiate...But drugmakers warn it could create regional shortages of some drugs if large pharmacy chains or distributors horde medications to beat the price increase. That would create an environment for speculators to drive prices up, not down.

In the waning days of summer in 2008, a convicted felon and his business partner leased office space on a seedy block near MacArthur Park. They set up a waiting room, hired an elderly physician and gave the place a name that sounded like an ordinary clinic: Lake Medical...The doctor began prescribing the opioid painkiller OxyContin – in extraordinary quantities. In a single week in September, she issued orders for 1,500 pills, more than entire pharmacies sold in a month. In October, it was 11,000 pills. By December, she had prescribed more than 73,000, with a street value of nearly $6 million...Purdue Pharma, the maker of OxyContin, tracked the surge in prescriptions. A sales manager went to check out the clinic and the company launched an investigation. It eventually concluded that Lake Medical was working with a corrupt pharmacy in Huntington Park to obtain large quantities of OxyContin.

• Sounding the alarm
• What Purdue knew
• Pills prescribed by Santiago
• Following the pills
• The skid row connection
• Pharmacist complaints
• Reports of concern
• ‘I was sitting on a gold mine.’
• ‘It really takes the ‘G’ a long time to catch up with these jokers’

...the reason a pharmacy prepares a specific concentration of an i.v. or oral liquid medication has little to do with clinical or patient safety considerations...the pharmacy staff follows standard recipes because "they've always done it that way," said Pasko, director of ASHP's Center on Medication Safety and Quality and principal investigator for ASHP's Standardize 4 Safety campaign...Pasko hopes the campaign will change that mindset and result in consistency, at the national level, in how i.v. and oral liquid admixtures are formulated for patient use..."We're really trying to emphasize to everyone that this is a patient safety effort,"..."We're putting patients at risk every day when we dispense a different concentration than what someone else does."...Standardize 4 Safety has put together an interprofessional panel of experts to propose voluntary, evidence-based standardized concentrations for 32 i.v. medications associated with a high risk of patient harm due to dosage errors...ASHP has urged pharmacists to get involved with the Standardize 4 Safety community through its online communication platform on ASHP Connect...

President Barack Obama today declared in a special issue of JAMA that the Affordable Care Act has worked, both by driving down the share of Americans without health coverage and by "transforming healthcare payment systems," that are improving quality and reining in spending...The president’s article, "United States Health Care Reform: Progress to Date and Next Steps," highlights what he sees as the achievements of the signature law often called "Obamacare," while calling for more work to cut prescription drug prices and fill gaps where market competition is lacking, perhaps with a "public option."..."Americans can now count on access to health coverage throughout their lives, and the federal government has an array of tools to bring the rise of healthcare costs under control," Obama writes. "However, the work toward a high-quality, affordable healthcare system is not over."

One of the experts, Dr. Gregory Terman, said he was dismissed Tuesday afternoon by phone. He said he was told the decision was made because his nonprofit group, the American Pain Society, receives funding from drugmakers...A group advising the Food and Drug Administration on medical issues abruptly dropped four experts from a panel on prescription painkillers after concerns emerged about apparent ties to the pharmaceutical industry...Federal advisers are supposed to be vetted for financial ties that can influence their judgment. Senator Ron Wyden of Oregon sent a letter Friday to the academies’ leadership noting that two of the panel nominees had also served in professional societies that receive funding from drugmakers. Wyden has protested industry influence on federal expert panels before.

Worldwide, less than half of Type 2 diabetes patients are taking their medicines in an "optimal" manner, according to a new report, leaving plenty of room for improvement for stakeholders seeking to reduce the billions of dollars associated with poor drug adherence...the IMS Institute for Healthcare Informatics said "sub-optimal" drug adherence is resulting in a "significant economic and societal burden" plus "avoidable" disease complications for patients...less than 40% of patients around the world are fully complying with their treatment instructions...ready to listen to the suggestions are health officials who've been seeking ways to pay for new, groundbreaking medicines without breaking the bank. Cutting down on avoidable costs would seem to make an approachable target in that effort...

Justin Gallagher, associate publisher of The American Journal of Managed Care. Welcome to This Week in Managed Care from the Managed Markets News Network

After two confirmed U.S. cases of a superbug that thwarts a last-resort antibiotic, infectious disease experts say they expect more cases in coming months because the bacterial gene (mcr-1) behind it is likely far more widespread than previously believed...Army scientists...reported finding E. coli bacteria that harbor a gene which renders the antibiotic colistin useless...The mcr-1 superbug has been identified over the past six months in farm animals and people in about 20 countries...Health officials fear the mcr-1 gene, carried by a highly mobile piece of DNA called a plasmid, will soon be found in bacteria already resistant to all or virtually all other types of antibiotics, potentially making infections untreatable...Within the next two to three years, it's going to be fairly routine for infections to occur in the United States for which we have no (effective) drugs available...mcr-1 will find its way into carbapenem-resistant bacteria…the resulting virtually impervious bacterium would likely spread slowly inside the United States because CRE themselves are not yet widespread in the country, giving drugmakers some time to create new antibiotics...